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ABSTRACT
Introduction: Intrapericardial fibrinolysis has been
proposed as a means of preventing complications of
pericardial effusion such as cardiac tamponade,
persistent and recurrent pericardial effusion, and
pericardial constriction. There is a need to understand
the efficacy and safety of this procedure because it
shows promise.
Methods and analysis: We aim to assess the effects
of intrapericardial fibrinolysis in the treatment of
pericardial effusion. We will search PubMed, the
Cochrane Library, African Journals online, Cumulative
Index to Nursing and Allied Health Literature, Trip
database, Clinical trials.gov and the WHO International
Clinical Trials Registry Platform for studies that
evaluate the efficacy and/or safety of complete
pericardial fluid drainage by intrapericardial fibrinolysis
irrespective of study design, geographical location,
language, age of participants, aetiology of pericarditis
or types of fibrinolytics. Two authors will do the search
independently, screen the search outputs for potentially
eligible studies and assess whether the studies meet
the inclusion criteria. Discrepancies between the two
authors will be resolved through discussion and
arbitration by a third author. Data from the selected
studies shall be extracted using a standardised data
collection form which will be piloted before use. The
methodological quality of studies will be assessed
using the Cochrane Collaboration’s tools for assessing
risk of bias for experimental studies and non-
randomised studies, respectively. The primary meta-
analysis will use random effects models due to
expected interstudy heterogeneity. Dichotomous data
will be analysed using relative risk and continuous with
data mean differences, both with 95% CIs.
Ethics and dissemination: Approval by an ethics
committee is not required for this study as it is a
protocol for a systematic review of published studies.
The results will be disseminated through a
conference presentation and peer-reviewed
publication.
Review registration number: PROSPERO,
CRD42014015238.
BACKGROUND
The era of HIV has seen an increase in the
incidence of pericarditis.1 The main cause of
pericarditis in Africa is tuberculosis.2
Pericarditis may complicate to tamponade in
the short term, and chronic effusive pericar-
ditis and constrictive pericarditis in the long
term. Cardiac tamponade and constrictive
pericarditis lead to death if not treated in
time. The deﬁnitive management of con-
strictive pericarditis involves pericardiectomy,
which is associated with a mortality of up to
14%3 and is an expensive procedure.4 Imazio
et al5 have shown that tuberculous and puru-
lent pericarditis are more likely to progress
Strengths and limitations of this study
▪ The planned review will shed light on the evi-
dence to date regarding the efficacy and safety of
intrapericardial fibrinolysis in preventing compli-
cations of pericardial effusion, and guide future
research on this theme.
▪ This manuscript is prepared according to the
recent Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols (PRISMA-P)
Statement.
▪ Unbiased selection of many studies conducted in
different settings will strengthen the validity of
the review results.
▪ The main limitation of the planned review will be
the heterogeneity of the settings and designs of
included studies.
Kakia A, et al. BMJ Open 2016;6:e007842. doi:10.1136/bmjopen-2015-007842 1
Open Access Protocol
group.bmj.com on August 3, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
to constrictive pericarditis than pericarditis due to other
causes. Ntsekhe et al6 found a 10.9% incidence of con-
strictive pericarditis over a 6-month period in patients
with pericardial effusions that were presumed to be
tuberculous. These ﬁndings highlight the importance of
efforts to prevent progression of pericarditis to constrict-
ive pericarditis.
Various strategies have been used to prevent progres-
sion of acute pericarditis to constrictive pericarditis.
Early diagnosis and prompt treatment of pericarditis,
including treating the underlying cause and draining of
effusions, are a major step in this direction. The use of
colchicine as adjunctive treatment to prevent recurrent
and persistent pericarditis, and thereby reducing the
risk of constriction, showed promise in a randomised
clinical trial conducted by Imazio et al.7 Corticosteroids
have been found to be useful in several trials; however,
the ﬁndings of Mayosi et al8 have shown that corticoster-
oids could increase the risk of cancers in patients coin-
fected with HIV.
Intrapericardial ﬁbrinolysis has been proposed as a
way of stemming the development of cardiac tamponade
and constriction in patients with effusive pericarditis.
The objective of ﬁbrinolysis is to target ﬁbrin formation,
to optimise evacuation of a thick ﬂuid, and therefore to
prevent both persistent purulent pericarditis and con-
strictive pericarditis.9 The procedure is also minimally
invasive. A clinical review conducted by Augustin et al9
concluded that intrapericardial ﬁbrinolysis may be
useful for prevention of constrictive pericarditis. Cui
et al10 investigated the efﬁcacy of intrapericardial ﬁbrin-
olysis in preventing constrictive pericarditis in patients
with infective pericardial effusion, 60% of which were of
tuberculous origin. They found that the early employ-
ment of ﬁbrinolysis optimised complete evacuation of
the pericardial effusion, signiﬁcantly reduced progress
to pericardial constriction and was safe.
In view of the promise held by intrapericardial ﬁbrin-
olysis, there is currently a need to better understand the
safety and efﬁcacy of the procedure. We propose, there-
fore, to conduct a systematic review to assess the efﬁcacy
and safety of intrapericardial ﬁbrinolysis in the preven-
tion of complications of pericardial effusion such as
cardiac tamponade, recurrent or persistent effusion,
constrictive pericarditis, hospitalisation and death.
OBJECTIVES
1. To determine whether complete pericardial drainage
by intrapericardial ﬁbrinolysis reduces the incidence
of cardiac tamponade, persistent or recurrent peri-
cardial effusion, constrictive pericarditis, hospitalisa-
tion and death in patients with pericardial effusion.
2. To determine whether complete pericardial drainage
by intrapericardial ﬁbrinolysis can be performed
safely with respect to the incidence of haemorrhage,
procedure-related cardiac tamponade, allergy and
serious and non-serious adverse events.
3. To determine the appropriate timing, dose and
volume of intrapericardial ﬁbrinolysis.
METHODS
Types of studies
We will consider primary studies with the following
designs:
▸ Intervention studies: randomised controlled trials
(RCTs), and quasi-RCTs.
▸ Observational studies: case reports, cohort studies,
case–control studies and cross-sectional studies.
Types of participants
People of all ages requiring intrapericardial ﬁbrinolysis
for evacuation of pericardial effusion due to any cause.
Study settings
We will include studies that evaluate the efﬁcacy and/or
safety of intrapericardial ﬁbrinolysis for preventing con-
strictive pericarditis irrespective of geographical
location.
Types of interventions
All types of ﬁbrinolytics will be considered including
(but not limited to) urokinase, streptokinase and tissue
plasminogen activator.
Types of outcome measures
The efﬁcacy outcomes of interest to this review are
cardiac tamponade, persistent or recurrent pericardial
effusion, constrictive pericarditis, hospitalisation and
death in patients with pericardial effusion.
The safety outcomes will be the incidence of haemor-
rhage, procedure-related cardiac tamponade, allergy,
serious and non-serious adverse events.
Search methods for identification of studies
We will develop a comprehensive strategy to search for
all eligible studies available up to the search date,
regardless of language or publication status. For pub-
lished literature we will search the electronic databases
PubMed, Cochrane Library (Cochrane Central Register
of Controlled Trials, Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects
(DARE)), African Journals online (AJOL), Cumulative
Index to Nursing and Allied Health Literature
(CINAHL) and Trip database. We will use a combination
of the following search terms and tailor them
appropriately to the different databases: ‘Pericarditis’,
‘tuberculous pericarditis,’ ‘purulent pericarditis,’ ‘peri-
cardiocentesis’, ‘therapeutic pericardiocentesis,’ ‘ﬁbrino-
lytics,’ ‘intrapericardial ﬁbrinolytics,’ ‘urokinase,’
‘streptokinase’ and ‘tissue plasminogen activator’. Box 1
below gives the provisional search strategy for PubMed,
which will be adapted for each electronic database. To
avoid selection bias, two authors will do the search inde-
pendently. To access unpublished literature, we will
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contact experts in the ﬁeld of therapeutic pericardiocen-
tesis and search Clinical trials.gov, and the WHO
International Clinical Trials Registry Platform.
Data collection and analysis
Two authors will independently screen the search
outputs for potentially eligible studies, compare their
results and resolve disagreements by discussion and con-
sensus. The two authors will then independently go
through the full text of all potentially eligible studies to
assess whether the studies meet the inclusion criteria
deﬁned by the study design, setting, intervention and
outcomes. Discrepancies in the list of eligible studies
between the two authors will be resolved through discus-
sion and consensus. A structured and standardised data
collection form shall be developed for extracting data
from the selected studies. The form will capture key
study characteristics, including study design, participants,
methods used for diagnosis of pericardial effusion (eg,
echocardiography), aetiology of effusions, interventions,
risk of bias and outcomes. Prior to use, the extraction
form will be piloted on at least three studies identiﬁed
randomly from the list of included studies.
The methodological quality of studies will be assessed
using the Cochrane Collaboration’s tool for assessing
risk of bias for experimental studies11 and the
‘Cochrane risk of bias assessment tool for non-
randomised studies of interventions’ for other study
designs.12
All eligible studies will be summarised and analysed
using the Cochrane Review Manager software.11 Two
authors will extract the data, one author will enter the
data and the second author will recheck the entries. In
the event of discrepancy, the authors shall discuss and
resolve the disagreement by discussion and consensus,
and if this fails to resolve the disagreement a third
author will arbitrate. If the studies are sufﬁciently
similar, we will combine the data using the random
effects model. We will examine statistical heterogeneity
between study results using the χ2 test of homogeneity
(with a signiﬁcance α-level of 0.1). We shall quantify stat-
istical heterogeneity between study results using the
inconsistency index (I2).13 14 When studies cannot be
combined for meta-analysis due to diversity of interven-
tions, narrative syntheses will be conducted.
We will stratify analysis by aetiology of pericardial effu-
sion (eg, tuberculous, bacterial), type of pericarditis (eg,
effusive, effusive constrictive), modality for diagnosis of
pericardial effusions and constriction (eg, use of echo-
graphy, echography not used) and study design (eg, con-
trolled trials, observational studies). For any
meta-analysis involving 10 or more studies, we will use
funnel plots to assess the possibility of publication bias.
In addition, we will apply the GRADE system to assess
the strength of the evidence from the review.15
Reporting of protocol and systematic review
We plan to report the ﬁndings of the review as recom-
mended in the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines.16 In
addition, we prepared the review protocol according to
the Preferred Reporting Items for Systematic review and
Meta-Analysis Protocols (PRISMA-P) statement.17
Ethics and dissemination
The planned systematic review is registered with the
International Prospective Register of Systematic Reviews
(PROSPERO), registration number CRD42014015238.
Systematic reviews draw on data available in the public
domain, and do not need formal ethical review and
approval. The ﬁndings of this systematic review will be
disseminated through peer-reviewed journal publications
and conference presentations. To our knowledge, no sys-
tematic review on intrapericardial ﬁbrinolysis for the
prevention of complications of pericardial effusion has
been performed to date. Our discussion of the ﬁndings
shall be in the light of the relevance of these data in
clinical decision-making, and the future research design
and direction on this topic.
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Box 1 Provisional search strategy for PubMed
(((((((pericardiocentesis) OR ‘pericardial drainage)’ OR ‘intraperi-
cardial fibrinolysis)’ OR fibrinolysis)) OR ((((‘tissue plasminogen
activator)’ OR urokinase) OR streptokinase) OR fibrinolytics)))
AND ((((((((((((pericarditis) OR ‘tuberculous pericarditis)’ OR
‘pericardial effusion)’ OR ‘TB pericarditis)’ OR ‘purulent pericardi-
tis)’ OR ‘complicated pericarditis)’ OR ‘complications of pericardi-
tis)’ OR ‘complications of pericardial effusions)’ OR ‘constrictive
pericarditis)’ OR ‘recurrent pericardial effusions)’ OR ‘persistent
pericarditis)’ OR ‘cardiac tamponade)’.
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